SCHEMBL5043715

SCHEMBL5043715

CCCCNC(=O)c1cc(-c2csc(-c3ccc(OC)cc3)n2)n(Cc2ccccc2)c1C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.50
ALDH1A1 P00352 2/20 0.50
KLKB1 P03952 6/20 0.49
TP53 P04637 3/20 0.46
MAPT P10636 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KMT2A Q03164 1/20 0.46
HTR2A P28223 3/20 0.44
HTR2C P28335 3/20 0.44
SLC6A4 P31645 3/20 0.44
EIF4E P06730 1/20 0.43
AGTR1 P30556 1/20 0.43
AGTR2 P50052 1/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 1/20 0.43
KLK1 P06870 2/20 0.42
IDH1 O75874 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046032 0.96 KLKB1 (0.53) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5044576 0.94 KLKB1 (0.49) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5048635 0.93 MAPT (0.50) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5048674 0.93 HPGD (0.51) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5043859 0.92 HPGD (0.53) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5044293 0.92 HPGD (0.49) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5044444 0.92 HPGD (0.50) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5043928 0.91 HPGD (0.48) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5048621 0.91 KLKB1 (0.48) HPGDALDH1A1KLKB1TP53MAPT
SCHEMBL5043812 0.91 HPGD (0.53) HPGDALDH1A1KLKB1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP claimed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US claimed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US claimed
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R HPGD 2000/4885ALDH1A1 959/4885KLKB1 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.